[Federal Register Volume 65, Number 58 (Friday, March 24, 2000)]
[Notices]
[Pages 15898-15899]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-7319]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Navy


Government-Owned Invention Available for Licensing

AGENCY: Department of the Navy, DOD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of the Navy hereby gives notice of the general 
availability of exclusive or partially exclusive licenses under the 
following pending patent. Any license granted shall comply with 35 
U.S.C. 209 and 37

[[Page 15899]]

CFR part 404. Applications will be evaluated utilizing the following 
criteria: (1) Ability to manufacture and market the technology; (2) 
manufacturing and marketing ability; (3) time required to bring 
technology to market and production rate; (4) royalties; (5) technical 
capabilities; and (6) small business status.
    Serial No. 94/39011 entitled ``A Recombinant Polypeptide For Use in 
the Manufacture of Vaccines Against Campylobacter-induced Diarrhea and 
to Reduce Colonization'' by Lee, Guerry, Berg and Trust filed 15 July 
1997. This technology represents an effective vaccine and treatment 
against Campylobacter diarrhea and comprises a recombinant fusion 
protein of the maltose binding protein (MBP) of E.coli fused to amino 
acids 5-337 of the FlaA flagellin of Campylobacter coli VC167. This 
fusion protein has provided evidence of immunogenicity and protective 
efficacy against challenge by a heterologous strain of Campylobacter 
jejuni 81-176 in mammals. The technology avoids the technical problem 
of inducing the autoimmune Guillain Barre Syndrome (GBS), a post-
infection polyneuropathy caused by Campylobacter molecular mimicry of 
human gangliosides. The technology includes a recombinant DNA construct 
encoding the immunodominant region of flagellin conserved across the 
Campylobacter species; expression--systems; methods for inducing an 
immune response through injectable, intranasal, and oral formulations; 
and a method for reducing Campylobacter intestinal colonization.

DATES: Applications for an exclusive or partially exclusive license may 
be submitted at any time from the date of this notice.

ADDRESSES: Navy Medical Research Center (NMRC), 503 Robert Grant Ave, 
Silver Spring, MD 20910-7500.

FOR FURTHER INFORMATION CONTACT: CDR Charles J. Schlagel, Office of 
Technology Transfer, NMRC, phone (301) 319-7427, fax (301) 319-7432, e-
mail [email protected].

    Dated: March 10, 2000.
J.L. Roth,
Lieutenant Commander, Judge Advocate General's Corps, U.S. Navy, 
Federal Register Liaison Officer.
[FR Doc. 00-7319 Filed 3-23-00; 8:45 am]
BILLING CODE 3810-FF-P